ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 2695 • ACR Convergence 2025

    B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents

    Carlo Tur1, Markus Eckstein2, Laura Bucci1, Janina Auth3, Christina Bergmann1, Simon Rauber4, Melanie Hagen1, Danae-Mona Nöthling1, Sebastian Böltz1, Andreas Wirsching1, Filippo Fagni5, Giulia Corte6, Panagiotis Garantziotis1, Jule Taubmann7, jochen wacker1, Andreas Ramming8, Maria Antonietta D'Agostino9, Arndt Hartmann10, Fabian Müller11, Andreas Mackensen12, Ricardo Grieshaber-Bouyer13, Georg Schett14, Aline Bozec1 and Maria Gabriella Raimondo1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 2Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 4Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Bayern, Germany, 5Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, 6- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 7Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 8Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) & Universitätsklinikum Erlangen, Erlangen, Germany, 9Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 10Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 11University Hospital of Erlangen, Erlangen, Germany, 12Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, 13University Hospital Erlangen, Erlangen, Germany, 14Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: Advanced protein-based therapies targeting B-cells, including glycoengineered CD20 monoclonal antibody obinutuzumab (OBI) and the CD19/CD3 T-cell engager blinatumumab (BLI), show promise for managing severe…
  • Abstract Number: 2579 • ACR Convergence 2025

    Mutant COPA Permits Aberrant NETosis and Exacerbates Autoimmune Lung Disease

    Richard Moore1, Lihong Huo1, Colin Koziel1, Barry Stripp2, Tiphanie Vogel3, Daniel Wallace4 and Caroline Jefferies5, 1Cedars-Sinai, Beverly Hills, CA, 2Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 3Baylor College of Medicine, Houston, TX, 4Cedars Sinai Medical Center, Studio City, CA, 5Cedars-Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: COPA syndrome is an autosomal dominant disease caused by missense mutations within the COPA gene. Typical onset begins during childhood with patients developing lung…
  • Abstract Number: 2459 • ACR Convergence 2025

    Hydroxychloroquine Discontinuation in Systemic Lupus Erythematosus: A Retrospective Cohort Study with 3-Year Follow-Up

    Milena Delai1, Rachel Simon1, Eduardo Mantovani Cardoso2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, 3Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

    Background/Purpose: Hydroxychloroquine (HCQ) plays an important role in the immunomodulation of Systemic Lupus Erythematosus (SLE), reducing the risk of flares and overall mortality. However, long-term…
  • Abstract Number: 2279 • ACR Convergence 2025

    Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial

    Koray Tascilar1, Mikkel Ostergaard2, Verena Schoenau3, Uta Kiltz4, Xenofon Baraliakos4, David Kofler5, Martin Feuchtenberger6, Ulrike Steffen7, Mario Zaiss8, Michael Zaenker9, Reinhard Voll10, Cornelia. Glaser11, Holger Bang12, Eugen feist13, Gerd Burmester14, Kirsten Karberg15, Joachim Strunk16, Juan Cañete17, Esperanza Naredo18, Mária Filková19, Ladislav Šenolt19, Georg Schett20 and Juergen Rech7, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, 2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark, and Copenhagen Center for Arthritis Research, Center for Rheumatology, Rigshospitalet, Glostrup, Denmark, 3- Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, 4Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 5University of Cologne, Cologne, Germany, 6MED | BAYERN OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany, Burghausen, Bayern, Germany, 7Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, 81Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, Erlangen, Bayern, Germany, 9Immanuel Klinikum Bernau , Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany, Berlin, Germany, 10University Medical Center Freiburg, Freiburg, Germany, 11Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, Freiburg, Baden-Wurttemberg, Germany, 12Orgentec, Mainz, Germany, 13Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 14Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 15Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany, Berlin, Germany, 16Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany, Köln-Porz, Germany, 17Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, 18Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute FJD-UAM, Madrid, Spain, MADRID, Spain, 19Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 20Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: A 6-month intervention with abatacept in the ARIAA trial (EUDRA-CT 2014–000555–93) significantly retarded the development of RA compared to placebo in ACPA-positive individuals with…
  • Abstract Number: 1967 • ACR Convergence 2025

    Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging

    Saahil Sachdeva1, Briana Cervantes2, Lisa Rider3 and Adam Schiffenbauer4, 1NIEHS/NIBIB/NIH, Danville, CA, 2Department of Emergency Medicine, Norfolk, VA, 3National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, 4National Institute of Health/National Institute of Dental and Craniofacial Research, Bethesda, MD

    Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle and skin inflammation. One potential complication of DM is calcinosis, the heterotopic calcification…
  • Abstract Number: 1777 • ACR Convergence 2025

    Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus

    Touraj Khosravi1, Ahmed Eldaboush2, Darae Kang3 and Victoria Werth2, 1Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3University of Pennsylvania, Potomac, MD

    Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
  • Abstract Number: 1649 • ACR Convergence 2025

    Does Physical Activity Differ Among those with Autoimmune vs Non-Autoimmune Rheumatic Diseases?

    Sydney Liles1, Jennifer Copson2, Yvonne Lee3 and Daniel K. White1, 1University of Delaware, Newark, DE, 2University of Delaware, Wilmington, DE, 3Northwestern University, Chicago, IL

    Background/Purpose: Individuals with rheumatic conditions, such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA), often experience low physical activity levels. Physical activity may vary by autoimmune…
  • Abstract Number: 1501 • ACR Convergence 2025

    Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes – Results from Real World Data

    Milad Heydari-Kamjani1, Amir Daneshvar2, Chelsea Guan2, Elleson Harper2, Keri Ann Pfeil2, Lindsay Frumker3, Meghan Gump2 and Omer Pamuk1, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 3University hospitals Cleveland medical center, Highland Heights, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous hematologic manifestations. Thrombocytopenia (TP) in SLE may be associated with major organ involvement and…
  • Abstract Number: 1348 • ACR Convergence 2025

    Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study

    Rieke Alten1, Gerd Burmester2, Marco Matucci-Cerinic3, Jens Gerwien4, Walid Fakhouri4, Samuel Ogwu4, Ewa Haladyj4, Inmaculada De La Torre4, Bruno Fautrel5 and AJ Fernandez4, 1SCHLOSSPARK KLINK, Teaching Hospital of University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, 2Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3University San Raffaele Milano, Milano, Milan, Italy, 4Eli Lilly and Company, Indiana Polis, IN, 5Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS 1136-5, PARIS, France, Paris, France

    Background/Purpose: Here, we provide descriptive baseline characteristics and effectiveness outcomes of Baricitinib (BARI) and other ts/bDMARDs at 24-month (24M) in both European (EU) and non-European…
  • Abstract Number: 1168 • ACR Convergence 2025

    Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory

    Karis Lee1, Min Kyung Lee2 and Stanley Naides3, 1Labcorp, Orlando, FL, 2Labcorp, Durham, NC, 3Labcorp, Dana Point, CA

    Background/Purpose: Interstitial lung disease (ILD) is frequent in systemic autoimmune rheumatic diseases (SARDs) and is associated with poor prognosis. The prevalence of ILD is approximately…
  • Abstract Number: 1052 • ACR Convergence 2025

    “Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use

    Isabella Hartel1, Jay Patel1, Justin Levinson1, Sancia Ferguson2, Carmen Campbell1, Amannda Weber3, Shelby Gomez4, David Gazeley5, Ali Duarte-Garcia6, Jennifer Barton7 and Shivani Garg8, 1University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, 3University of Wisconsin (UW), UW Health, Madison, WI, 4University of Wisconsin, School of Pharmacy, Madison, WI, 5Medical College of Wisconsin, Milwaukee, WI, 6Mayo Clinic, Rochester, MN, 7VA Portland Health Care System/OHSU, Portland, OR, 8University of Madison, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…
  • Abstract Number: 0949 • ACR Convergence 2025

    The Cancer-associated Female-biased Factor VGLL3 Drives Autoimmunity and Fibrosis

    Mehrnaz Gharaee-Kermani1, Poulami Dey2, Vincent van Drongelen1, Joanna Rew1, Rachael Bogle3, Marisa Hildebrandt1, Benjamin Klein1, Rezvan Moallemian1, Monique E Verhaegen1, Andrzej A Dlugosz4, Lam Tsoi1, J. Michelle Kahlenberg1, Johann Gudjonsson1 and Allison C Billi1, 1University of Michigan, Ann Arbor, MI, 2Michigan Medicine, Ann Arbor, MI, 3University of Michigan, Holland, OH, 4University of Michigan, Ann Arbor

    Background/Purpose: Autoimmune disease is far more common in women than men. We have determined that the skin of healthy women is primed for autoimmunity due…
  • Abstract Number: 0906 • ACR Convergence 2025

    Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease

    Yao Xiong, Shuaixiang Zhou, Zhimin Zhang, Bin Li, Zhihao Ming, Yuyu Wu, Liu Li, Chang Li, Fenggen Fu, Zhihai Wu, Shun Wang, Guogang Yuan, Yuling Song, Jinyang Li, Huizhong Xiong and Bingliang Chen, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)

    Background/Purpose: Dysregulated B-cell activation plays a pivotal role in the pathogenesis of various autoimmune diseases. B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are…
  • Abstract Number: 0608 • ACR Convergence 2025

    Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients

    Elena Heras Recuero1, Antia Garcia Fernandez2, Cristina Gomez-Moreno3, Ivan Ferraz Amaro4, Javier Llorca5 and Miguel A. González-Gay6, 1Hospital Fundacion Jimenez Dias, Madrid, Spain, 2Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, 6Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain

    Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
  • Abstract Number: 0792 • ACR Convergence 2025

    Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases

    Tania Chiha1, Jiaqi Wang2, Isha Jha3, Grace McMahon3, John Stone4 and Naomi Patel3, 1Mount Auburn Hospital, Boston, MA, 2Massachusetts General Hospital, BOston, 3Massachusetts General Hospital, Boston, MA, 4Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: Glucocorticoids (GC) are used to treat various inflammatory and autoimmune diseases, though despite widespread use, real-world data on skin-specific GC toxicity are limited. To…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology